Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

61. Unfractionated Heparin and Low-Molecular-Weight Heparin

Unfractionated Heparin and Low-Molecular-Weight Heparin © 2013 Thrombosis Canada. Page 1 of 5 UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients. ABBREVIATIONS: ALT alanine aminotransferase aPTT activated partial thromboplastin time AST aspartate aminotransferase AT antithrombin CBC complete blood count HIT heparin (...) -induced thrombocytopenia INR international normalized ratio IV intravenous LMWH low-molecular-weight heparin MI myocardial infarction PT prothrombin time TNK tenecteplase tPA tissue plasminogen activator UFH unfractionated heparin U units VTE venous thromboembolism MECHANISM OF ACTION: Unfractionated heparin (UFH) acts as an anticoagulant by forming a complex with antithrombin (AT) catalysing the inhibition of several activated blood coagulation factors: thrombin (factor IIa), factor IXa, Xa, XIa

2015 Thrombosis Interest Group of Canada

62. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system Full Text available with Trip Pro

Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system To characterize heparin-induced thrombocytopenia (HIT) at a single pediatric center including the prevalence and the accuracy of the 4Ts scoring system as a predictor of HIT.In this retrospective cohort study, we identified 155 consecutive patients <21 years old with sufficient data for 4Ts scoring. The 4Ts scoring system is a validated pretest tool in adults that predicts (...) the likelihood of HIT using clinical features. Hospital-wide exposure to unfractionated and low molecular weight heparin was determined by querying the hospital pharmacy database.The majority of patients with suspected HIT (61.2%) were on surgical services. Prediction of HIT risk using initial 4Ts scoring found 3 (2%) had high risk 4Ts scores, 114 (73%) had intermediate risk 4Ts scores, and the remaining 38 (25%) had low risk 4Ts scores. HIT was confirmed in 0/38 patients with low risk 4Ts scores, 2/114

2015 EvidenceUpdates

63. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. Full Text available with Trip Pro

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting

2015 JAMA

64. Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy

Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Article

2015 Evidence-Based Medicine

65. PROPATEN heparin-bonded vascular graft for peripheral arterial disease

PROPATEN heparin-bonded vascular graft for peripheral arterial disease PR PROP OPA ATEN heparin-bonded vascular gr TEN heparin-bonded vascular graft for aft for peripher peripheral arterial disease al arterial disease Medtech innovation briefing Published: 13 October 2015 nice.org.uk/guidance/mib42 pathways Summary Summary The Gore PROPATEN heparin-bonded vascular graft is a synthetic graft used to treat peripheral arterial disease by bypassing damaged blood vessels. The graft is made from (...) expanded polytetrafluoroethylene (ePTFE) that has a layer of heparin anticoagulant bonded to its inner surface, which is designed to reduce graft occlusion. Relevant evidence was limited and consisted of 1 randomised controlled trial and 5 cohort studies, with either artificial graft or autologous vein graft comparators. The reports indicate that the PROPATEN graft is either equivalent or inferior to autologous vein grafts in maintaining patency (that is, remaining open and functional over time

2015 National Institute for Health and Clinical Excellence - Advice

66. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial Full Text available with Trip Pro

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial Venous thromboembolism (VTE) is common in cancer patients. Evidence has suggested that low molecular weight heparin (LMWH) might improve survival in patients with cancer by preventing both VTE and the progression of metastases. No trial in a single cancer type has been powered to demonstrate a clinically significant survival difference. The aim of this trial

2015 EvidenceUpdates Controlled trial quality: predicted high

67. Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study Full Text available with Trip Pro

Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings

2014 EvidenceUpdates Controlled trial quality: uncertain

68. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Full Text available with Trip Pro

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Venous thromboembolism (VTE) is a common complication of acute illness, and its prevention is a ubiquitous aspect of inpatient care. A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference (...) in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin.To evaluate the comparative cost-effectiveness of LMWH vs UFH for prophylaxis against VTE in critically ill patients.Prospective economic evaluation concurrent with the Prophylaxis for Thromboembolism in Critical Care Randomized Trial (May 2006 to June 2010). The economic evaluation adopted a health care payer

2014 JAMA

69. Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity. (Abstract)

Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity. Heparin is an anticoagulant medication that is normally injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma and pain at the injection site. One of the factors that may affect pain, haematoma and bruising is injection speed.To assess the effects of the duration (speed) of subcutaneous heparin injection on pain, haematoma (...) and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin or low molecular weight heparin.The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). We searched MEDLINE, EMBASE, CINAHL and two Persian databases Iranmedex and SID (August 2013).We sought randomised controlled trials (RCTs) comparing the effects of different durations

2014 Cochrane

70. Heparin versus normal saline for patency of arterial lines. Full Text available with Trip Pro

Heparin versus normal saline for patency of arterial lines. For most patients who require intensive care, the success of clinical decision making and interventions is dependent on the accuracy of different physiological variables measured or obtained from samples using an arterial catheter. Maintaining the patency of these catheters is therefore essential for obtaining accurate measures, minimizing patient discomfort and reducing expenses incurred when an occluded catheter requires replacement (...) . Uncertainty exists amongst clinicians as to best practice surrounding the contents of the arterial catheter flush solution (heparin or saline). The use of heparin is more expensive and is accompanied by significant risks such as haemorrhage, hypersensitivity and heparin-induced thrombocytopenia (HIT).The objective of this review was to evaluate whether normal saline is as efficacious and safe as heparin in maintaining the patency of arterial intravascular catheters in adult patients without

2014 Cochrane

71. Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty

Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Deep vein thrombosis (DVT) is a blood clot, or thrombus, that forms in a deep vein most commonly in the legs. DVT is serious since

2014 Health Technology Assessment (HTA) Database.

72. Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. (Abstract)

Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. The prevalence of children diagnosed with deep vein thrombosis or pulmonary embolism has been increasing in the last decade. The most common thrombosis risk factor in neonates, infants and children is the placement of a central venous catheter (CVC). To date, it is unknown if the practice of anticoagulation prophylaxis with low molecular weight heparin (LMWH) decreases CVC-related

2014 Cochrane

73. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness

Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism (...) : a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies

2014 Health Technology Assessment (HTA) Database.

74. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety

Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness (...) and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary

2014 Health Technology Assessment (HTA) Database.

75. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness

Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT (...) and PE: a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs

2014 Health Technology Assessment (HTA) Database.

76. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati (Abstract)

Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati Heparin-induced thrombocytopenia (HIT) is diagnosed using clinical criteria and detection of platelet-activating anti-platelet factor 4/heparin (anti-PF4/H) antibodies, usually through a surrogate enzyme-linked immunosorbent assay (ELISA

2014 EvidenceUpdates

77. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. (Abstract)

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Bivalirudin, with selective use of glycoprotein (GP) IIb/IIIa inhibitor agents, is an accepted standard of care in primary percutaneous coronary intervention (PPCI). We aimed to compare antithrombotic therapy with bivalirudin or unfractionated heparin during this procedure.In our open-label, randomised controlled trial, we enrolled (...) consecutive adults scheduled for angiography in the context of a PPCI presentation at Liverpool Heart and Chest Hospital (Liverpool, UK) with a strategy of delayed consent. Before angiography, we randomly allocated patients (1:1; stratified by age [<75 years vs ≥75 years] and presence of cardiogenic shock [yes vs no]) to heparin (70 U/kg) or bivalirudin (bolus 0·75 mg/kg; infusion 1·75 mg/kg per h). Patients were followed up for 28 days. The primary efficacy outcome was a composite of all-cause mortality

2014 Lancet Controlled trial quality: predicted high

78. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup Full Text available with Trip Pro

Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup The hypothesis that endovascular treatment with covered stents has equal risks but higher efficacy than bare-metal stents (BMS) in long femoropopliteal artery disease was tested.Although endovascular treatment of short superficial femoral (...) artery lesions revealed excellent results, efficacy in long lesions remains unsatisfactory.In a prospective, randomized, single-blind, multicenter study, 141 patients with symptomatic peripheral arterial disease were assigned to treatment with heparin-bonded, covered stents (Viabahn 72 patients) or BMS (69 patients). Clinical outcomes and patency rates were assessed at 1, 6, and 12 months.Mean ± SD lesion length was 19.0 ± 6.3 cm in the Viabahn group and 17.3 ± 6.6 cm in the BMS group. Major

2013 EvidenceUpdates Controlled trial quality: predicted high

79. Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety

Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety TITLE: Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety DATE: 02 July 2013 CONTEXT AND POLICY ISSUES Low molecular weight heparins (LMWH) have emerged as an important alternative to unfractionated heparin (...) . LMWH are at least as effective antithrombotic drugs as UFH, however, it is still unclear whether the safety profiles of LMWH and UFH differ. 12 The important adverse events of heparin includes heparin-induced thrombocytopenia (HIT), an adverse drug reaction presenting as a prothrombotic disorder related to antibody-mediated platelet activation, 13 and bleeding. In 2009, CADTH published a review on the cost-effectiveness of LMWH compared with UFH. 11 It was reported in that review that LMWH appeared

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

80. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. (Abstract)

Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. Antithrombotic agents are frequently used for preventing vascular occlusion. Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. Its benefit in microvascular

2013 Cochrane